Pete, I believe the Yahoo author is incorrect rega

Pete, I believe the Yahoo author is incorrect regarding the 10-day dosage of remdesivir. The SOC for remdesivir in the U.S. for CV19 is for a 5-day treatment which IMO is due to 2 key points. Firstly, Gilead could not show any benefit in efficacy by increasing days dosed from 5 to 10 days. Secondly there are safety issues with remdesivir at its current 5-day regiment which would further increase with expanded dosage. Remember that remdesivir did not show improvements in mortality or viral load reduction and was originally approved based on reduction of hospital days from 15 to 11 days. Net/net increasing remdesivir dosage further elevates safety issues and does not improve efficacy.

In contrast, Brilacidin appears to be safe at much higher doses than what was allowed in the Phase 2 trial and also appears to gain efficacy as dosage and frequency are increased. Hopefully the safety and efficacy improvements will be validated in Compassionate Use data and possibly in secondary trial data. Improvements in inflammation markers could also be a major differentiator above and beyond any antiviral improvements.

https://www.covid19treatmentguidelines.nih.go...anagement/